Nanexa announced today that, due to the Covid situation at Uppsala University Hospital, the study start at the trials Uppsala site has been delayed. However, the start at the site at Karolinska University Hospital in Huddinge remains unaffected as of today (start by end of April). Nanexa is now in dialogue with Karolinska to see if the hospital can take a larger share of the trial. While it is unfortunate that the readout could be delayed, it does not change our valuation at this stage.